Coherus Biosciences | CHRS - Trade Debtors


Coherus Biosciences reported $18.42M in Trade Debtors for its fiscal quarter ending in December of 2025.





Trade Debtors Change Date
AbbVie USD 12.48B 110M Mar/2026
Acadia Pharmaceuticals USD 148.38M 153K Mar/2026
Akebia Therapeutics USD 47.03M 19.19M Dec/2025
ALKERMES USD 456.48M 48.85M Jun/2026
Alnylam Pharmaceuticals USD 912.74M 28.78M Jun/2026
Amarin USD 126.83M 477K Dec/2025
Amgen USD 9.14B 432M Mar/2026
Baxter International USD 1.86B 158M Jun/2026
Biogen USD 1.79B 76.6M Mar/2026
BioMarin Pharmaceutical USD 903.91M 4.3M Mar/2026
Bristol-Myers Squibb USD 13.83B 535M Jun/2026
Coherus Biosciences USD 18.42M 232.08M Dec/2025
Eli Lilly USD 21.18B 1.02B Mar/2026
Fujifilm JPY 887.02B 64.37B Mar/2026
Gilead Sciences USD 4.74B 172M Mar/2026
Ironwood Pharmaceuticals USD 81.89M 5.68M Dec/2024
Merck USD 11.78B 345M Dec/2025
Myriad Genetics USD 115.3M 2.7M Dec/2025
Pacira USD 125.64M 1.57M Mar/2026
Perrigo USD 697.1M 84.3M Mar/2026
Pfizer USD 16.17B 332M Mar/2026
PTC Therapeutics USD 219.92M 38.3M Mar/2026
Regeneron Pharmaceuticals USD 6.57B 834.4M Jun/2026
Sarepta Therapeutics USD 547.91M 149.68M Mar/2026
Teva Pharmaceutical Industries USD 3.49B 100M Jun/2026
Vertex Pharmaceuticals USD 2B 56.7M Mar/2026
Xencor USD 12M 17.3M Mar/2026
Zoetis USD 1.51B 84M Mar/2026